Evidence map›Paper›PMID 38561753›Full record

ArticleHarm reduction journal2024

Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry.

R J Fredericksen, R Baker, A Sibley, A T Estadt, D Colston, L S Mixson, S Walters, J Bresett, X A Levander, G Leichtling and 13 more

Open access · goldAbstract read
In one paragraph

Article in Harm reduction journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Effects of opioids and stimulants on the respiratory system.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 1 country.

R J FredericksenUniversity of Washington, Seattle, USA. rfrederi@uw.edu.
R BakerOregon Health & Science University, Portland, USA.
A SibleyUniversity of North Carolina at Chapel Hill, Chapel Hill, USA.
A T EstadtThe Ohio State University, Colombus, USA.
D ColstonUniversity of North Carolina at Chapel Hill, Chapel Hill, USA.
L S MixsonUniversity of Washington, Seattle, USA.
S WaltersNew York University, New York, USA.
J BresettSouthern Illinois University School of Medicine, Springfield, USA.
X A LevanderOregon Health & Science University, Portland, USA.
G LeichtlingComagine Health, Portland, OR, USA.
T Davy-MendezUniversity of North Carolina at Chapel Hill, Chapel Hill, USA.
M PowellUniversity of Washington, Seattle, USA.
T J StopkaTufts University School of Medicine, Department of Public Health and Community Medicine, Medford, USA.
M PhoUniversity of Chicago, Chicago, USA.
J FeinbergWest Virginia University, Morgantown, USA.
J EzellCornell University, Ithaca, USA.
W ZuleUniversity of North Carolina at Chapel Hill, Chapel Hill, USA.
D SealTulane University, New Orleans, USA.
H L F CooperEmory University, Atlanta, USA.
B M WhitneyUniversity of Washington, Seattle, USA.
J A C DelaneyUniversity of Washington, Seattle, USA.
H M CraneUniversity of Washington, Seattle, USA.
J I TsuiUniversity of Washington, Seattle, USA.
Seattle University · USUniversity of North Carolina at Chapel Hill · USOregon Health & Science University · USUniversity of Washington · USCornell University · USEmory University · USNew York University · USSouthern Illinois University School of Medicine · USThe Ohio State University · USTufts University · USTulane University · USUniversity of Chicago · USWest Virginia University · US

Funding

Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC)UH3DA044829 · NIDA · UNIVERSITY OF CHICAGO · PI JENKINS, WILEY, PHO, MAI TUYET · 2019 to 2022
$5.2M
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)UH3DA044798 · NIDA · UNIVERSITY OF KENTUCKY · PI COOPER, HANNAH LF, YOUNG, APRIL MARIE · 2019 to 2022
$4.4M
From Biological to Social Processes: Interdisciplinary Training in Life Course ResearchT32HD091058 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT A HUMMER, Amanda L Thompson · 2017 to 2026
$4.3M
NW Center of Excellence & K12 in Patient Centered Learning Health Systems ScienceK12HS026370 · AHRQ · OREGON HEALTH & SCIENCE UNIVERSITY · PI EDEN, KAREN BEEKMAN, GUISE, JEANNE-MARIE · 2018 to 2022
$4.0M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0M
Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)UH3DA044830 · NIDA · BAYSTATE MEDICAL CENTER, INC. · PI FRIEDMANN, PETER D, STOPKA, THOMAS J · 2019 to 2022
$3.9M
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)U24DA048538 · NIDA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., TSUI, JUDITH · 2019 to 2023
$3.7M
Next-Generation Sequencing Center for GHOSTing Hepatitis C Virus: Transforming Community Based Molecular Surveillance and Outbreak InvestigationU24DA044801 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI ALLEN, TODD M · 2017 to 2022
$3.3M
Community-based, client-centered prevention homes to address the rural opioid epidemicUH3DA044826 · NIDA · UNIVERSITY OF WISCONSIN-MADISON · PI SEAL, DAVID W, WESTERGAARD, RYAN PATRICK · 2019 to 2022
$2.6M
Learning from the COVID-19 pandemic to improve emergency management planning for harm reduction services in rural OhioUH3DA044822 · NIDA · OHIO STATE UNIVERSITY · PI GO, VIVIAN F., MILLER, WILLIAM C · 2019 to 2022
$2.5M
Mitigating the Outcomes Associated with the Injection Drug Use Epidemic in Southern AppalachiaUH3DA044823 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZULE, WILLIAM A · 2019 to 2021
$2.4M
Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)UG3DA044830 · NIDA · BAYSTATE MEDICAL CENTER, INC. · PI FRIEDMANN, PETER D · 2017 to 2018
$1.6M
AHRQ HHS K12 HS026370NHLBI NIH HHS K01 HL169020NICHD NIH HHS T32 HD091058NIDA NIH HHS U24 DA044801NIDA NIH HHS U24 DA048538NIDA NIH HHS U24DA048538NIDA NIH HHS UG3 DA044798NIDA NIH HHS UG3DA044798NIDA NIH HHS UG3 DA044823NIDA NIH HHS UG3DA044823NIDA NIH HHS UG3 DA044825NIDA NIH HHS UG3DA044825NIDA NIH HHS UG3 DA044826NIDA NIH HHS UG3DA044826NIDA NIH HHS UG3 DA044829NIDA NIH HHS UG3DA044829NIDA NIH HHS UG3 DA044830NIDA NIH HHS UG3DA044830NIDA NIH HHS UG3 DA044831NIDA NIH HHS UG3DA044831NIDA NIH HHS UH3 DA044798NIDA NIH HHS UH3 DA044822NIDA NIH HHS UH3DA044822NIDA NIH HHS UH3 DA044823NIDA NIH HHS UH3 DA044826NIDA NIH HHS UH3 DA044829NIDA NIH HHS UH3 DA044830NIDA NIH HHS UH3 DA044831
6 · The paper itself

Abstract

backgroundIn recent years, stimulant use has increased among persons who use opioids in the rural U.S., leading to high rates of overdose and death. We sought to understand motivations and contexts for stimulant use among persons who use opioids in a large, geographically diverse sample of persons who use drugs (PWUD) in the rural settings.

methodsWe conducted semi-structured individual interviews with PWUD at 8 U.S. sites spanning 10 states and 65 counties. Content areas included general substance use, injection drug use, changes in drug use, and harm reduction practices. We used an iterative open-coding process to comprehensively itemize and categorize content shared by participants related to concurrent use.

resultsWe interviewed 349 PWUD (64% male, mean age 36). Of those discussing current use of stimulants in the context of opioid use (n = 137, 39%), the stimulant most used was methamphetamine (78%) followed by cocaine/crack (26%). Motivations for co-use included: 1) change in drug markets and cost considerations; 2) recreational goals, e.g., seeking stronger effects after heightened opioid tolerance; 3) practical goals, such as a desire to balance or alleviate the effects of the other drug, including the use of stimulants to avoid/reverse opioid overdose, and/or control symptoms of opioid withdrawal; and 4) functional goals, such as being simultaneously energized and pain-free in order to remain productive for employment.

conclusionIn a rural U.S. cohort of PWUD, use of both stimulants and opioids was highly prevalent. Reasons for dual use found in the rural context compared to urban studies included changes in drug availability, functional/productivity goals, and the use of methamphetamine to offset opioid overdose. Education efforts and harm reduction services and treatment, such as access to naloxone, fentanyl test strips, and accessible drug treatment for combined opioid and stimulant use, are urgently needed in the rural U.S. to reduce overdose and other adverse outcomes.

Indexed as

Central Nervous System StimulantsDrug OverdoseMethamphetamineOpiate OverdoseOpioid-Related DisordersAdultAnalgesics, OpioidDrug ToleranceFemaleHumansMaleMotivationUnited StatesAnalgesics, OpioidCentral Nervous System StimulantsMethamphetamineConcurrent stimulant and opioid useMethamphetamine usePolydrug useRural

Identifiers

PMID38561753
PMCPMC10985853
OpenAlexW4393386647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.